MaltSci 麦伴科研

Appearance

Popular Reports / Clinical Medicine

This report is written by MaltSci based on the latest literature and research findings

What are the latest treatments for diabetes? ​

Abstract ​

Diabetes mellitus (DM) represents a significant global health challenge, with a marked increase in prevalence projected to affect approximately 500 million individuals by 2030. The complexity of diabetes management, particularly type 2 diabetes (T2D), necessitates effective treatment strategies to mitigate the risk of severe complications. Recent advancements in diabetes therapies have shifted from traditional approaches to more innovative, personalized modalities. This review outlines the current pharmacological treatments, including insulin therapy, oral hypoglycemic agents, and emerging classes such as GLP-1 receptor agonists and SGLT2 inhibitors. These treatments aim to enhance glycemic control while addressing associated comorbidities. Lifestyle modifications, encompassing dietary interventions and physical activity, are emphasized as integral components of diabetes management. Additionally, the role of emerging technologies, including continuous glucose monitoring systems and automated insulin delivery systems, is explored, highlighting their impact on patient care. Personalized medicine approaches, considering genetic and biomarker factors, are discussed to optimize treatment outcomes. The review concludes with a focus on the challenges and future directions in diabetes management, advocating for continued research to address treatment adherence and the integration of innovative therapies into clinical practice.

Outline ​

This report will discuss the following questions.

  • 1 Introduction
  • 2 Current Pharmacological Treatments
    • 2.1 Insulin Therapy
    • 2.2 Oral Hypoglycemic Agents
    • 2.3 Newer Classes of Medications (e.g., GLP-1 receptor agonists, SGLT2 inhibitors)
  • 3 Lifestyle Modifications
    • 3.1 Dietary Interventions
    • 3.2 Physical Activity and Exercise
    • 3.3 Behavioral Therapy
  • 4 Emerging Technologies in Diabetes Management
    • 4.1 Continuous Glucose Monitoring (CGM)
    • 4.2 Insulin Pumps and Automated Delivery Systems
    • 4.3 Digital Health and Mobile Applications
  • 5 Personalized Medicine Approaches
    • 5.1 Genetic and Biomarker Considerations
    • 5.2 Tailored Treatment Strategies
    • 5.3 Patient-Centered Care Models
  • 6 Challenges and Future Directions
    • 6.1 Addressing Treatment Adherence
    • 6.2 Managing Comorbidities
    • 6.3 Research Gaps and Future Innovations
  • 7 Conclusion

1 Introduction ​

Diabetes mellitus (DM) has emerged as a significant global health challenge, characterized by chronic hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The World Health Organization has reported a dramatic rise in diabetes prevalence, with projections indicating that by 2030, approximately 500 million people will be living with diabetes worldwide[1]. This increase is particularly notable for type 2 diabetes (T2D), which accounts for approximately 90-95% of all diabetes cases. The multifactorial nature of diabetes, involving genetic, environmental, and lifestyle factors, underscores the complexity of its management and the urgent need for effective treatment strategies[2][3].

The significance of advancing diabetes treatment cannot be overstated. Effective management of diabetes is crucial not only for improving glycemic control but also for reducing the risk of severe complications such as cardiovascular disease, neuropathy, and nephropathy, which can significantly impair quality of life and increase healthcare costs[4]. Recent years have witnessed substantial advancements in diabetes therapies, shifting from traditional approaches towards more innovative and personalized treatment modalities. The introduction of novel pharmacological agents, lifestyle modifications, and technological innovations has transformed the landscape of diabetes management, offering new hope for patients and healthcare providers alike[5][6].

Current research indicates a shift towards understanding the underlying mechanisms of diabetes, which has paved the way for the development of new therapeutic classes. Pharmacological treatments have expanded beyond conventional insulin therapy and oral hypoglycemic agents to include glucagon-like peptide-1 (GLP-1) receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, and other emerging therapies that target novel pathways of glucose regulation[7][8]. These advancements not only aim to improve glycemic control but also to address associated comorbidities and enhance overall patient outcomes[8][9].

This review is organized into several key sections. The first section will provide an overview of current pharmacological treatments, detailing the mechanisms, efficacy, and safety profiles of insulin therapy, oral hypoglycemic agents, and newer classes of medications such as GLP-1 receptor agonists and SGLT2 inhibitors. The second section will discuss lifestyle modifications, including dietary interventions, physical activity, and behavioral therapy, emphasizing their role in diabetes management. The third section will explore emerging technologies in diabetes management, such as continuous glucose monitoring systems, insulin pumps, and digital health applications, which are revolutionizing patient care and self-management practices[10][11].

The fourth section will focus on personalized medicine approaches, examining genetic and biomarker considerations, tailored treatment strategies, and patient-centered care models. This discussion will highlight the importance of individualized therapy in optimizing treatment outcomes for diverse patient populations[9][12]. Finally, the review will address the challenges and future directions in diabetes management, including issues related to treatment adherence, the management of comorbidities, and ongoing research gaps that need to be addressed to further advance the field[3][13].

In conclusion, the evolving landscape of diabetes treatment necessitates continuous updates and adaptations in clinical practice. By synthesizing the latest evidence and expert opinions, this review aims to provide healthcare professionals and researchers with a comprehensive understanding of current and emerging diabetes therapies, ultimately fostering the adoption of evidence-based practices in the management of this chronic disease.

2 Current Pharmacological Treatments ​

2.1 Insulin Therapy ​

Recent advancements in diabetes treatment have primarily focused on enhancing insulin therapy and introducing new pharmacological options. Insulin therapy remains the cornerstone of treatment for both type 1 and type 2 diabetes, and significant progress has been made in this area over the past few decades.

Insulin, discovered in 1921, revolutionized diabetes management, particularly for type 1 diabetes. However, challenges such as the need for treatment flexibility, the risk of hypoglycemia, and the overall quality of life for patients persist. Innovations in insulin therapy have included the development of new insulin analogs that offer ultra-rapid and ultra-long-acting formulations, improving glycemic control while reducing the frequency of hypoglycemic episodes. These advancements allow for better simulation of physiological insulin secretion patterns, which is crucial for effective diabetes management [14].

Moreover, the combination of insulin with incretin-based therapies has emerged as a promising approach for managing type 2 diabetes. Incretins, such as GLP-1 receptor agonists and DPP-4 inhibitors, enhance glucose-lowering effects without significantly increasing the risk of hypoglycemia. This strategy not only complements the action of insulin but also allows for lower doses of insulin, which can mitigate concerns related to weight gain commonly associated with insulin therapy [15].

Recent reviews have highlighted the importance of targeting pancreatic β cells to enhance diabetes treatment. Efforts to regenerate or protect these insulin-producing cells are underway, as current therapies primarily focus on insulin replacement rather than addressing the underlying dysfunction in β cells [16]. Research has shown that pharmacological interventions that enhance β cell proliferation and protect against cell death may offer new avenues for treatment [16].

Additionally, innovative approaches such as gene therapy, stem cell therapy, and islet transplantation are being explored. These methods aim to restore or replace the function of β cells, potentially providing a curative strategy for diabetes rather than just symptomatic relief [2]. For type 2 diabetes, a variety of pharmacological agents are available that work through different mechanisms, including stimulating insulin secretion, reducing hepatic glucose production, and improving insulin sensitivity [2].

In summary, the landscape of diabetes treatment is evolving, with significant advancements in insulin therapy and the integration of new pharmacological agents that target various pathways involved in glucose metabolism. These developments not only aim to improve glycemic control but also enhance the overall quality of life for individuals living with diabetes. The ongoing research and clinical trials continue to shape the future of diabetes management, emphasizing personalized therapy and innovative treatment strategies [5][17].

2.2 Oral Hypoglycemic Agents ​

Currently available oral agents for the treatment of type 2 diabetes mellitus include a variety of compounds from five different pharmacologic classes, each with differing mechanisms of action, adverse effect profiles, and toxicities. These oral antidiabetic drugs can be classified into two main categories: hypoglycemic agents, which include sulfonylureas and benzoic acid derivatives, and antihyperglycemic agents, which consist of biguanides, alpha-glucosidase inhibitors, and thiazolidinediones [18].

Epidemiologic and interventional studies have led to lower treatment targets for type 2 diabetes, which now include a glycosylated hemoglobin level of 7 percent or less and a before-meal blood glucose level of 80 to 120 mg per dL (4.4 to 6.7 mmol per L). New oral medications such as acarbose, metformin, miglitol, pioglitazone, rosiglitazone, and troglitazone assist the patient's own insulin in controlling glucose levels, facilitating early treatment with minimal risk of hypoglycemia. Additionally, two new long-acting sulfonylureas (glimepiride and extended-release glipizide) and a short-acting sulfonylurea-like agent (repaglinide) augment the patient's insulin supply effectively [19].

A systematic review identified that oral hypoglycemic agents and orlistat are the only drugs studied in randomized controlled trials with diabetes incidence as the primary endpoint. The findings from studies with durations of 2.5 to 4.0 years indicate that metformin (relative risk [RR] 0.69), acarbose (RR 0.75), troglitazone (RR 0.45), and orlistat (hazard ratio [HR] 0.63) significantly decrease diabetes incidence compared to placebo. However, the long-term efficacy of these agents in reducing morbidity and mortality associated with late complications remains to be fully substantiated [20].

Recent advancements in oral pharmacologic management have introduced new classes of agents that address the pathophysiology of hyperglycemia in type 2 diabetes, which includes insulin deficiency, excess hepatic glucose output, and insulin resistance. New agents focus on stimulating insulin secretion, reducing hepatic glucose production, delaying digestion and absorption of carbohydrates, and improving insulin action. Among these are incretin-based therapies, SGLT2 inhibitors, and glucokinase activators [21].

While the initial effectiveness of oral hypoglycemic agents is highest in patients who have had diabetes for less than five years, are overweight at treatment initiation, and whose fasting blood glucose levels are below 200 mg/dl, the transition from insulin to oral compounds can be successful, particularly if the insulin dosage has been less than 20 to 30 units daily [22].

In summary, the current landscape of oral hypoglycemic agents for the treatment of type 2 diabetes is diverse and evolving, with a focus on personalized treatment approaches that consider the individual patient's characteristics and the pharmacological profiles of available agents.

2.3 Newer Classes of Medications (e.g., GLP-1 receptor agonists, SGLT2 inhibitors) ​

Recent advances in the treatment of type 2 diabetes mellitus (T2DM) have led to the development of several new pharmacological agents, particularly focusing on glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose co-transporter 2 (SGLT2) inhibitors. These medications not only improve glycemic control but also provide additional health benefits, including cardiovascular and renal protection.

GLP-1 receptor agonists, such as semaglutide and liraglutide, enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety, which collectively aid in weight loss and better glycemic control. These agents have shown significant cardiovascular benefits, as they can reduce the risk of major adverse cardiovascular events in patients with established cardiovascular disease [23][24]. The newer GLP-1 receptor agonists are also being developed in formulations that allow for less frequent dosing or oral administration, which may improve patient adherence to treatment [25].

SGLT2 inhibitors, such as empagliflozin and canagliflozin, work by preventing glucose reabsorption in the kidneys, leading to increased glucose excretion in urine and reduced blood glucose levels. These agents have demonstrated significant reductions in heart failure admissions and major cardiovascular events among patients with T2DM and existing cardiovascular disease [24][26]. SGLT2 inhibitors are also associated with renal protection, making them a vital component of the treatment regimen for patients with T2DM who have a high risk of cardiovascular and renal complications [27].

In addition to these established classes, the pharmacotherapy landscape for T2DM is continuously evolving. Newer agents, such as the dual GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, are currently under investigation and have shown promise in improving glycemic control and promoting weight loss more effectively than GLP-1 receptor agonists alone [26][27]. Moreover, various drug classes are in different stages of clinical development, focusing on novel mechanisms of action and therapeutic targets [28].

The treatment of T2DM now emphasizes a multifaceted approach, integrating lifestyle modifications with pharmacological therapies to manage glucose levels, weight, and cardiovascular risk factors. The current strategies aim not only to lower HbA1c levels but also to provide long-term clinical benefits and ensure cardiovascular safety [8][29]. As the understanding of T2DM pathophysiology improves, the future of diabetes treatment is likely to incorporate more personalized medicine approaches, considering individual patient characteristics and comorbidities [30].

3 Lifestyle Modifications ​

3.1 Dietary Interventions ​

The management of diabetes, particularly type 2 diabetes mellitus (T2DM), has evolved significantly, with lifestyle modifications and dietary interventions playing a crucial role in treatment strategies. The recent literature emphasizes the importance of these modifications alongside pharmacological therapies to achieve optimal glycemic control and improve overall health outcomes.

Lifestyle modifications encompass a range of interventions aimed at promoting healthier behaviors, which are essential in the management of diabetes. A combination of physical activity, weight management, and dietary changes is recommended to help patients control their blood glucose levels effectively. Evidence indicates that extensive lifestyle changes, including weight reduction and increased physical activity, can lead to the remission of diabetes. Such lifestyle changes have been shown to mitigate the burden of diabetes on individuals and health care systems, although questions remain regarding the long-term maintenance of these changes and their effects on diabetic complications (Vasdeki et al., 2022) [31].

Dietary interventions have also undergone significant evolution, guided by advancements in understanding the biochemical and physiological mechanisms of glucose metabolism. Recent dietary guidelines for diabetes management emphasize a more liberal use of sucrose, aligning with healthy eating recommendations for the general population. The focus is on promoting monounsaturated fats as the preferred fat source and encouraging the consumption of carbohydrate foods with a low glycemic index. Structured educational programs are recommended to facilitate dietary changes, demonstrating effectiveness in reducing the progression of diabetes and its complications (Moran, 2004) [32].

Moreover, the introduction of new classes of glucose-lowering agents has complemented lifestyle interventions, providing additional options for managing diabetes. While traditional treatments like metformin remain foundational, newer pharmacological agents, including incretin-based therapies and SGLT-2 inhibitors, have shown promise in improving glycemic control and reducing weight (Chawla et al., 2024) [33]. These medications can enhance the effectiveness of lifestyle changes by addressing insulin resistance and promoting weight loss.

In summary, the latest treatments for diabetes integrate lifestyle modifications and dietary interventions as fundamental components of a comprehensive management strategy. The emphasis on personalized multimodal care, including dietary changes, exercise, and pharmacotherapy, aims to improve patient outcomes and achieve remission in T2DM, reflecting a significant shift in the approach to diabetes management (Odegard et al., 2006; Tegegne et al., 2024) [11][34].

3.2 Physical Activity and Exercise ​

The management of diabetes, particularly type 2 diabetes mellitus (T2DM), increasingly emphasizes lifestyle modifications, including physical activity and exercise, as critical components of treatment. Recent literature highlights the significant role that lifestyle changes play in achieving glycemic control and mitigating the complications associated with diabetes.

Physical activity is a cornerstone of lifestyle modification strategies. Engaging in regular exercise helps improve insulin sensitivity, facilitates weight loss, and can lower blood glucose levels. The American Diabetes Association and the European Association for the Study of Diabetes advocate for lifestyle modifications as a preferred first-line therapy, alongside metformin, which remains the primary pharmacological treatment for T2DM [35].

Moreover, research indicates that comprehensive lifestyle interventions, which include not only exercise but also dietary changes, can lead to remission in T2DM. These interventions are often coupled with intensive glucose-lowering therapies and may include bariatric surgery for obese patients, which has shown effectiveness in achieving significant weight loss and improving metabolic outcomes [31].

The increased prevalence of diabetes, driven by factors such as obesity and sedentary lifestyles, necessitates a focus on these non-pharmacological strategies. Studies suggest that sustained physical activity can lead to improved long-term health outcomes, including reduced risks of cardiovascular disease and other diabetes-related complications [36].

In conclusion, while pharmacological advancements in diabetes treatment are significant, the integration of lifestyle modifications, particularly physical activity and exercise, remains essential for effective diabetes management. The combination of these strategies not only enhances glycemic control but also addresses the broader aspects of health and well-being in individuals with diabetes.

3.3 Behavioral Therapy ​

Recent literature highlights the critical role of lifestyle modifications and behavioral therapies in the management of diabetes, particularly type 2 diabetes mellitus (T2DM). The multifactorial nature of diabetes necessitates a comprehensive approach that includes both pharmacological and non-pharmacological strategies.

Lifestyle modifications are foundational in diabetes management. A combination of dietary changes, increased physical activity, and behavior therapy has been shown to induce a mean weight loss of 7-10% in individuals with obesity, which significantly reduces the risk of developing T2DM in those with impaired glucose tolerance [37]. Standard behavioral interventions (SBTs) are based on first and second wave behavioral therapies, focusing on supporting effective lifestyle changes such as adherence to healthful behaviors, medication regimens, and self-monitoring [38].

Furthermore, "third wave" therapies, particularly acceptance-based therapies (ABTs), have emerged as a promising novel approach for diabetes management. These therapies integrate techniques from acceptance and commitment therapy and may enhance medication adherence and promote effective lifestyle changes [38]. This innovative strategy is proposed as a means to improve glucose control through a more holistic understanding of the psychological aspects of diabetes management.

The American Diabetes Association emphasizes that lifestyle modification, alongside pharmacological treatments like metformin, remains the preferred first-line therapy for T2DM [35]. This combination approach not only addresses the immediate glycemic control but also aims to mitigate the long-term complications associated with diabetes.

In addition to traditional behavioral strategies, there is an increasing recognition of the importance of addressing psychological factors that influence diabetes management. Interventions that focus on behavioral change are essential for improving patient compliance and treatment outcomes [39].

The evidence supports the notion that achieving good metabolic control requires sustained lifestyle changes, which can be challenging for many patients. Therefore, personalized care plans that include behavioral therapies tailored to individual needs are crucial for effective diabetes management [40].

In summary, the latest treatments for diabetes emphasize the importance of lifestyle modifications and behavioral therapies as integral components of a comprehensive management strategy. These approaches not only improve adherence to treatment regimens but also enhance the overall quality of life for individuals living with diabetes.

4 Emerging Technologies in Diabetes Management ​

4.1 Continuous Glucose Monitoring (CGM) ​

Continuous Glucose Monitoring (CGM) has emerged as a transformative technology in the management of diabetes, particularly for individuals requiring insulin therapy. The latest advancements in CGM systems have significantly improved the accuracy, convenience, and effectiveness of glucose monitoring, ultimately enhancing patient outcomes.

Recent literature highlights that CGM technology has evolved to provide nearly continuous glucose measurements, allowing for real-time insights into blood glucose dynamics. These devices are equipped with features such as visual and auditory alarms for hypoglycemia, which enhance patient safety and enable timely interventions (Klonoff et al. 2017; Yoo & Kim 2023). Moreover, CGM systems facilitate better glycemic control by allowing patients to observe trends in their glucose levels, which is especially beneficial in managing diabetes during critical situations such as perioperative care or when undergoing nutrition therapy (Visser et al. 2024).

In addition to traditional CGM systems, the integration of CGM with insulin delivery mechanisms has led to the development of automated insulin delivery (AID) systems. These hybrid closed-loop systems utilize data from CGM to adjust insulin delivery automatically, thereby reducing the burden of manual input and improving glycemic control (Zahid et al. 2023). The potential of these systems to function like an artificial pancreas is a significant advancement in diabetes management, providing patients with a more autonomous and effective means of controlling their blood glucose levels (Kovatchev 2012).

The latest CGM devices are designed to be minimally invasive and user-friendly, which has contributed to their increasing adoption among patients with both type 1 and type 2 diabetes. Evidence indicates that the use of CGM can lead to improved glycemic outcomes, reduced incidence of hypoglycemia, and enhanced quality of life for patients (Agarwal et al. 2024; Galindo & Aleppo 2020). Furthermore, the combination of CGM with educational support has been shown to yield better results than CGM use alone, underscoring the importance of patient education in maximizing the benefits of this technology (Yoo & Kim 2023).

Despite these advancements, challenges remain in the widespread implementation of CGM in clinical practice, particularly in inpatient settings. Research suggests that logistical challenges and the need for staff training are barriers to integrating advanced diabetes technologies in hospitals (Visser et al. 2024). Therefore, further studies are essential to evaluate the efficacy, accuracy, and safety of CGM systems, as well as to address implementation factors such as cost and training requirements (Davis et al. 2020).

In summary, the latest developments in CGM technology represent a significant leap forward in diabetes management. These advancements not only improve glycemic control but also enhance patient safety and quality of life. As research continues to support the efficacy of CGM and related technologies, it is anticipated that their adoption will expand, ultimately leading to better diabetes management strategies across diverse patient populations.

4.2 Insulin Pumps and Automated Delivery Systems ​

Recent advancements in diabetes management have significantly transformed treatment options, particularly through the development of insulin pumps and automated insulin delivery systems (AID). These technologies are designed to enhance glycemic control, improve patient compliance, and reduce the burden of diabetes management.

Insulin pumps have evolved from basic devices to sophisticated systems capable of continuous subcutaneous insulin infusion (CSII). They allow for precise and flexible insulin dosing, which is crucial for intensive diabetes management. The benefits of insulin pump therapy include improved long-term glycemic control and a reduced risk of diabetes-related complications, along with increased lifestyle flexibility for patients and their families. Comprehensive patient education and frequent blood glucose monitoring are essential for successful outcomes with insulin pump therapy[41].

Automated insulin delivery systems represent a significant leap forward in diabetes technology. These systems integrate continuous glucose monitoring (CGM) with insulin delivery, allowing for real-time adjustments based on blood glucose levels. Recent developments in hybrid closed-loop systems are aimed at minimizing patient involvement, approaching the functionality of a fully automated artificial pancreas. These systems have shown potential in improving glycemic control and patient quality of life by reducing the need for manual insulin administration[42].

The use of continuous glucose monitoring has become increasingly prevalent, facilitating more accurate and patient-friendly follow-up and therapy titration. CGM systems enable patients to monitor their glucose levels in real-time, which is critical for making informed decisions about insulin dosing. The integration of CGM with insulin pumps in AID systems allows for automated adjustments to insulin delivery, thus optimizing treatment and enhancing overall diabetes management[43].

Moreover, advancements in diabetes technology have also focused on enhancing patient self-efficacy and satisfaction. Technologies such as smart insulin pens and connected devices are becoming more common, promoting better adherence to treatment regimens. These innovations not only improve glycemic control but also positively impact the quality of life for individuals living with diabetes[44].

In summary, the latest treatments for diabetes, particularly through the use of insulin pumps and automated insulin delivery systems, have made significant strides in enhancing patient care. These technologies offer improved glycemic control, reduce the complexity of diabetes management, and ultimately aim to empower patients in their treatment journey. As these technologies continue to evolve, further research and development will be necessary to maximize their efficacy and accessibility in clinical settings[45][46][47].

4.3 Digital Health and Mobile Applications ​

Recent advancements in diabetes management have increasingly focused on the integration of digital health technologies and mobile applications. These innovations aim to enhance patient care, improve glycemic control, and facilitate adherence to treatment regimens.

One significant area of development is the use of continuous glucose monitoring (CGM) systems and automated insulin delivery systems. These technologies have shown to substantially ease the burden of glucose measurement and insulin administration, thereby improving overall diabetes management. For instance, CGMs provide real-time data on glucose levels, allowing for more precise insulin dosing and better management of blood sugar fluctuations. The integration of CGMs with insulin pumps has led to the creation of hybrid closed-loop systems, which automate insulin delivery based on CGM readings, mimicking the function of a biological pancreas (Zahid et al., 2023; Lundgrin et al., 2025).

Additionally, smart or connected insulin pens have emerged as a promising tool for diabetes management. These devices are designed to improve the accuracy of insulin dosing and track administration data through mobile applications, enabling users to manage their insulin therapy more effectively. However, while the safety and efficacy of CGMs and continuous subcutaneous insulin infusion (CSII) therapies are well-established, the evidence supporting the latest digital healthcare tools, such as smart insulin pens, remains limited (Carlson et al., 2025).

Mobile health applications also play a crucial role in diabetes management. These applications can provide personalized health data, facilitate communication with healthcare providers, and offer educational resources to support self-management. They help improve patient engagement and adherence to treatment plans, which are essential for effective diabetes care (Eberle et al., 2021; Grant & Golden, 2019). Furthermore, digital tools have been shown to enhance the quality of life for individuals with diabetes by providing support for behavioral and emotional challenges associated with the condition (Gonder-Frederick et al., 2016).

Despite the potential benefits, there are challenges associated with the adoption of these technologies. Issues such as data security, interoperability among devices, and the cost of technology can hinder widespread implementation. Furthermore, limited clinical studies exist that specifically evaluate the efficacy and safety of newer devices, highlighting the need for further research to substantiate their benefits in diabetes management (Carlson et al., 2025; Lundgrin et al., 2025).

In summary, the latest treatments for diabetes are increasingly centered around digital health technologies and mobile applications, which enhance monitoring and management capabilities. As these technologies continue to evolve, they hold the promise of significantly improving outcomes for individuals with diabetes, although further research is necessary to fully realize their potential and address existing challenges.

5 Personalized Medicine Approaches ​

5.1 Genetic and Biomarker Considerations ​

The landscape of diabetes treatment is rapidly evolving, particularly with the advent of personalized medicine approaches that leverage genetic and biomarker considerations. Personalized medicine aims to tailor treatment strategies to individual patients based on their unique genetic makeup, biomarkers, and disease characteristics, thereby maximizing therapeutic efficacy and minimizing adverse effects.

In the context of type 2 diabetes (T2D), recent guidelines advocate for a shift from rigid treatment algorithms to a more personalized approach. This involves developing individualized treatment goals that encompass not only glycemic control but also weight management, prevention and treatment of comorbidities, and avoidance of complications such as hypoglycemia. Factors influencing treatment intensity and pharmacotherapy choices include the patient's diabetes phenotype, genetic biomarkers, and comorbid conditions, alongside patient-specific factors such as treatment preferences, age, and psychological circumstances [48].

For type 1 diabetes (T1D), the application of personalized medicine is particularly promising due to the disease's heterogeneous nature. Research has identified that individuals with T1D exhibit varying responses to treatments, highlighting the importance of personalized approaches. Current strategies focus on risk stratification for diabetes development, enabling early detection and intervention. Innovations such as gene therapy and stem cell therapies are being explored to prevent pancreatic destruction and regenerate pancreatic tissues, respectively [49].

Moreover, the role of genetic and pharmacogenetic considerations in diabetes treatment is gaining traction. Understanding the genetic underpinnings of drug response can inform treatment choices, particularly in monogenic forms of diabetes, where specific genetic markers guide therapy selection. For instance, certain genetic variants can predict responsiveness to specific medications, allowing for tailored pharmacotherapy that optimizes treatment outcomes [50].

Biomarkers also play a critical role in personalized diabetes management. Biomarkers such as C-peptide levels can guide treatment choices, while the identification of genetic variants associated with drug metabolism can help adjust medication dosages to reduce adverse effects and enhance therapeutic efficacy [51]. Furthermore, emerging research in 'omics' technologies, including genomics and metabolomics, promises to unravel the complex interactions that influence diabetes pathophysiology and treatment response [52].

The integration of these personalized approaches is expected to improve not only clinical outcomes but also patient satisfaction and adherence to treatment regimens. As research continues to evolve, the focus will be on refining these personalized strategies to address the unique needs of diverse patient populations, ultimately leading to more effective and individualized diabetes care [53][54].

In summary, the latest treatments for diabetes are increasingly characterized by personalized medicine approaches that utilize genetic and biomarker considerations to tailor interventions to individual patients, enhancing treatment efficacy and safety while addressing the complex nature of diabetes.

5.2 Tailored Treatment Strategies ​

Recent advancements in diabetes management have increasingly focused on personalized medicine approaches, emphasizing tailored treatment strategies that consider individual patient characteristics, preferences, and disease profiles. This shift from a "one-size-fits-all" model aims to enhance treatment efficacy and patient satisfaction, ultimately improving health outcomes.

In the context of Type 1 diabetes, personalized medicine is evolving to match insulin therapy to the unique needs of each patient. Recent research highlights the importance of understanding the genetic and autoimmune nature of Type 1 diabetes, which allows for the identification of biomarkers that can predict disease progression and response to therapy. For instance, autoantibodies are being utilized as predictive biomarkers to assess disease risk, facilitating the timing of interventions and the development of personalized treatment plans that align with individual disease trajectories [53].

For Type 2 diabetes (T2D), personalized management has gained traction through updated guidelines that advocate for individualized treatment goals rather than rigid algorithms. Clinicians are encouraged to collaborate with patients to establish personalized objectives related to glycemic control, weight management, and the prevention of complications [48]. Factors influencing treatment decisions include the patient's diabetes phenotype, genetic markers, and comorbid conditions, which all contribute to the selection of appropriate pharmacotherapies [48][55].

Recent innovations in diabetes technology, particularly continuous glucose monitoring (CGM) systems, have transformed diabetes care. These systems empower patients to manage their condition more effectively by providing real-time glucose data, which can inform insulin dosing decisions and improve glycemic control. The development of hybrid closed-loop systems represents a significant leap toward automated insulin delivery, enhancing patient autonomy and treatment precision [42].

Furthermore, the incorporation of "omics" technologies—such as pharmacogenomics—into diabetes management is paving the way for more refined therapeutic strategies. Genetic testing can help predict individual responses to various glucose-lowering medications, allowing clinicians to tailor drug selection based on a patient's genetic makeup. This approach has shown promise in identifying patients who are more likely to benefit from specific therapies, thereby optimizing treatment efficacy and minimizing adverse effects [50].

In summary, the latest treatments for diabetes are increasingly characterized by personalized medicine approaches that leverage genetic insights, advanced technologies, and patient-centered strategies. These developments not only aim to enhance glycemic control but also to improve overall patient well-being by addressing the unique needs and preferences of individuals living with diabetes. As research continues to unfold, the implementation of personalized strategies in clinical practice is expected to evolve, ultimately leading to more effective and sustainable diabetes management solutions.

5.3 Patient-Centered Care Models ​

Recent advancements in diabetes management have significantly shifted towards personalized medicine approaches, emphasizing patient-centered care models. These developments are particularly relevant for both type 1 and type 2 diabetes, where treatment strategies are increasingly tailored to individual patient needs, preferences, and unique disease characteristics.

For type 1 diabetes, personalized medicine is evolving through a better understanding of the disease's autoimmune nature and its genetic underpinnings. Advances in insulin delivery systems, continuous glucose monitoring (CGM), and the development of hybrid closed-loop systems are revolutionizing diabetes care. These technologies allow for more precise management of blood glucose levels, improving outcomes such as HbA1c, time in range, and glycemic variability while reducing the risk of hypoglycemia [56]. Furthermore, the integration of personalized approaches in treatment planning aims to match insulin therapy to the unique requirements of each individual, thereby enhancing overall management [54].

In type 2 diabetes, the landscape of personalized medicine is characterized by a focus on individual risk profiles and treatment responses. The management of hyperglycemia has become increasingly complex, with a growing arsenal of pharmacological agents available. However, the effectiveness of these treatments can vary significantly among individuals due to genetic, pathophysiological, and clinical heterogeneity [55]. A recent forum highlighted the necessity of a patient-centered approach, advocating for the customization of diabetes care based on the unique characteristics of each patient [57]. This includes the potential use of pharmacogenetic testing to tailor therapies based on individual responses to medications [55].

The concept of patient-centered care is further underscored by the recognition that intensive glycemic control does not necessarily correlate with improved patient outcomes. New evidence suggests that a moderate glycemic target, aligned with the patient's lifestyle and preferences, may provide better quality of life and reduce treatment burden [58]. This approach fosters shared decision-making, integrating clinical evidence with the patient's values and needs, which is essential for effective diabetes management [58].

Moreover, innovations in diabetes technology, such as smart insulin pens and daily patch pumps, are being developed to enhance personalized care. These technologies aim to simplify diabetes management, allowing for more effective and individualized treatment strategies [42]. The increasing availability of data from wearable devices and digital health platforms also supports the customization of care, providing insights that can inform treatment adjustments in real-time [42].

In conclusion, the latest treatments for diabetes reflect a paradigm shift towards personalized medicine and patient-centered care. By leveraging technological advancements and a deeper understanding of individual patient profiles, healthcare providers can offer more effective and tailored interventions, ultimately improving outcomes and quality of life for those living with diabetes.

6 Challenges and Future Directions ​

6.1 Addressing Treatment Adherence ​

The management of diabetes has seen significant advancements in recent years, particularly with the emergence of new treatment modalities aimed at improving glycemic control and addressing patient adherence to therapy. Traditional pharmacologic therapies such as insulin and oral antidiabetic agents remain in use; however, innovative approaches are now being developed to enhance treatment efficacy and patient compliance.

Recent literature highlights the introduction of connected ecosystems in diabetes management, which incorporate sophisticated insulin delivery systems, glucose monitoring technologies, telemedicine, and mobile health applications. These advancements aim to create a more personalized diabetes management experience, potentially increasing adherence to insulin therapy. A targeted review emphasized that these connected systems could help mitigate issues related to missed or delayed insulin doses, which are significant barriers to achieving optimal glycemic control. By integrating insulin data with contextual patient information, such as dietary intake and physical activity, these technologies promise to support more informed clinical decisions and improve overall diabetes management (Steenkamp et al., 2022) [59].

In addition to technological advancements, stem cell therapy is emerging as a promising approach for diabetes treatment. Stem cell-based therapies, particularly those utilizing induced pluripotent stem cells and mesenchymal stem cells, have shown potential in regenerating pancreatic islet cells and addressing both type 1 and type 2 diabetes. Despite the promise these therapies hold, challenges such as safety concerns, immune rejection, and the need for efficient transplantation methods remain significant hurdles to their widespread application (Zuo et al., 2025) [60].

Furthermore, there is ongoing research into novel therapeutic targets that could provide safer and more effective treatment options for diabetes. Recent studies have identified various new targets, including G protein-coupled receptors (GPCRs), which are being explored for their potential in insulin regulation and as future therapeutic agents. These developments indicate a shift towards a more targeted approach in diabetes treatment, focusing on specific pathways that could enhance drug efficacy and patient adherence (Dhankhar et al., 2023) [61].

Despite these advancements, low adherence to diabetes treatment remains a critical issue. Factors contributing to this problem include the complexity of treatment regimens, side effects of medications, and the overall burden of managing a chronic disease. Future directions in diabetes management will likely involve a combination of innovative treatment strategies, personalized medicine, and improved patient education to enhance adherence and ensure better health outcomes.

In conclusion, the landscape of diabetes treatment is evolving with the integration of technology, stem cell therapy, and novel pharmacological targets. However, addressing the challenges of treatment adherence will be crucial for the success of these emerging therapies in real-world settings.

6.2 Managing Comorbidities ​

Diabetes management has evolved significantly, particularly in addressing comorbidities and complications associated with the disease. Recent studies emphasize the need for a multifaceted approach that not only targets glycemic control but also considers the impact of comorbid conditions on diabetes treatment.

Current therapeutic strategies primarily focus on optimizing glycemic control through various pharmacological agents. Traditional treatments, such as insulin and oral hypoglycemic agents, have been used extensively; however, they often come with side effects that can complicate management, especially in older patients or those with multiple comorbidities. For instance, the presence of renal or liver disease limits the use of certain antihyperglycemic therapies, necessitating a cautious approach with insulin and sulfonylureas, while newer agents like sodium-glucose co-transporter 2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are gaining traction for their renal protective effects (Hussain & Chowdhury, 2019) [62].

Moreover, the management of diabetes-associated complications such as painful diabetic neuropathy (PDN) has seen the introduction of novel treatments. While first-line therapies like pregabalin and duloxetine remain common, newer approaches exploring alternative targets, such as the NMDA receptor and the endocannabinoid system, show promise in alleviating pain with potentially fewer side effects (Basem et al., 2023) [63].

Recent literature also highlights the role of lifestyle interventions alongside pharmacotherapy in managing diabetes and its comorbidities. These interventions are considered first-line treatments for many comorbid conditions associated with diabetes, emphasizing a holistic approach to patient care (Teck, 2022) [64]. The latest clinical practice guidelines advocate for a personalized medicine approach, tailoring treatment strategies based on individual patient profiles, including their comorbid conditions, life expectancy, and quality of life considerations (Yu et al., 2022) [65].

Additionally, emerging therapies derived from natural products, such as nobiletin and hesperetin, are being investigated for their potential benefits in managing diabetes and its complications. These compounds are of particular interest due to their minimal side effects and their ability to address multiple pathways involved in diabetes pathology (Zhao et al., 2025; Yang et al., 2022) [66][67].

Despite the advancements in diabetes management, challenges remain, particularly in the integration of these new therapies into clinical practice. The need for more extensive clinical trials to validate the efficacy and safety of emerging treatments, alongside ongoing education for healthcare providers on managing comorbidities, is critical. Future research directions will likely focus on refining treatment algorithms that consider the interplay between diabetes and its associated conditions, thereby enhancing patient outcomes and quality of life.

6.3 Research Gaps and Future Innovations ​

Diabetes mellitus, particularly type 2 diabetes (T2D), continues to present significant challenges due to its rising prevalence and associated complications. The landscape of diabetes treatment has evolved dramatically, with numerous innovative therapeutic approaches emerging in recent years. This response highlights the latest treatments for diabetes, challenges faced in the field, and future directions for research and innovation.

Recent advancements in diabetes management include a variety of new pharmacologic agents and treatment strategies. Traditional therapies such as insulin and oral antidiabetic medications, including metformin and sulfonylureas, remain widely used. However, the introduction of novel classes of drugs has revolutionized diabetes treatment. Notable among these are glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose co-transporter-2 (SGLT2) inhibitors. GLP-1 RAs not only enhance insulin secretion in response to meals but also promote weight loss and have shown cardiovascular benefits[6]. SGLT2 inhibitors, on the other hand, work by preventing glucose reabsorption in the kidneys, leading to increased glycosuria and improved glycemic control with a lower risk of hypoglycemia[12].

In addition to pharmacological innovations, newer treatment modalities are being explored, such as incretin-based therapies, which combine the effects of GLP-1 and gastric inhibitory polypeptide to target multiple metabolic defects associated with T2D[6]. Furthermore, emerging strategies like nanotechnology for drug delivery systems, stem cell therapy for β-cell regeneration, and gene therapy hold promise for more effective diabetes management[4].

Despite these advancements, several challenges persist in diabetes treatment. One major issue is the heterogeneity of diabetes, which necessitates personalized treatment approaches to address individual patient needs effectively[10]. Additionally, the risk of adverse effects from existing therapies, such as weight gain and hypoglycemia, continues to complicate treatment regimens and patient compliance[9].

Future directions in diabetes research should focus on addressing these challenges. Innovations in drug development should prioritize safety and efficacy, aiming to minimize side effects while maximizing therapeutic outcomes. There is a growing interest in combination therapies that utilize the synergistic effects of multiple agents to enhance glycemic control and reduce complications[13]. Moreover, exploring the potential of new drug classes and delivery systems through clinical trials will be crucial for identifying effective treatments that cater to diverse patient populations[10].

Research gaps also exist in understanding the long-term impacts of newer therapies on diabetes-related complications and the underlying mechanisms of drug response variability among individuals. Addressing these gaps will require collaborative efforts among researchers, clinicians, and policymakers to ensure that advancements in diabetes care translate into improved patient outcomes[8].

In conclusion, the field of diabetes treatment is rapidly evolving, with numerous innovative therapies and strategies emerging to combat this global health crisis. However, ongoing research is essential to overcome existing challenges and explore future innovations that can lead to more effective and personalized diabetes management.

7 Conclusion ​

The landscape of diabetes treatment has undergone significant transformations in recent years, characterized by the emergence of innovative pharmacological agents, lifestyle modifications, and technological advancements. Key findings indicate that while traditional therapies such as insulin and oral hypoglycemic agents remain foundational, the introduction of GLP-1 receptor agonists and SGLT2 inhibitors has provided new avenues for improving glycemic control and reducing complications. The integration of personalized medicine approaches, which consider genetic, biomarker, and patient-centered factors, has further enhanced treatment efficacy and adherence. Despite these advancements, challenges related to treatment adherence, management of comorbidities, and the need for ongoing research to address gaps in understanding and application persist. Future directions should focus on refining treatment strategies, enhancing patient education, and fostering collaborative efforts to ensure that innovations translate into better health outcomes for individuals with diabetes. The commitment to personalized, multifaceted care models will be essential in addressing the complexities of diabetes management and improving the quality of life for patients.

References ​

  • [1] Cheng Hu;Weiping Jia. Therapeutic medications against diabetes: What we have and what we expect.. Advanced drug delivery reviews(IF=17.6). 2019. PMID:30529309. DOI: 10.1016/j.addr.2018.11.008.
  • [2] Cristina M Sena;Carla F Bento;Paulo Pereira;Raquel Seiça. Diabetes mellitus: new challenges and innovative therapies.. The EPMA journal(IF=5.9). 2010. PMID:23199048. DOI: 10.1007/s13167-010-0010-9.
  • [3] Pragya Tiwari. Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update.. Journal of diabetes research(IF=3.4). 2015. PMID:26273667. DOI: 10.1155/2015/340838.
  • [4] Vijay Mishra;Pallavi Nayak;Mayank Sharma;Aqel Albutti;Ameen S S Alwashmi;Mohammad Abdullah Aljasir;Noorah Alsowayeh;Murtaza M Tambuwala. Emerging Treatment Strategies for Diabetes Mellitus and Associated Complications: An Update.. Pharmaceutics(IF=5.5). 2021. PMID:34683861. DOI: 10.3390/pharmaceutics13101568.
  • [5] Leslie S Satin;Scott A Soleimanpour;Emily M Walker. New Aspects of Diabetes Research and Therapeutic Development.. Pharmacological reviews(IF=17.3). 2021. PMID:34193595. DOI: 10.1124/pharmrev.120.000160.
  • [6] Geltrude Mingrone;Lidia Castagneto-Gissey;Stefan R Bornstein. New Horizons: Emerging Antidiabetic Medications.. The Journal of clinical endocrinology and metabolism(IF=5.1). 2022. PMID:36106900. DOI: 10.1210/clinem/dgac499.
  • [7] Juliana Cn Chan. What can we learn from the recent blood glucose lowering megatrials?. Journal of diabetes investigation(IF=3.0). 2011. PMID:24843455. DOI: 10.1111/j.2040-1124.2010.00063.x.
  • [8] Michael Lehrke;Nikolaus Marx. New antidiabetic therapies: innovative strategies for an old problem.. Current opinion in lipidology(IF=4.6). 2012. PMID:23069986. DOI: 10.1097/MOL.0b013e328359b19f.
  • [9] Alexander Kuhn;Jean Park;Adline Ghazi;Vanita R Aroda. Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?. Current cardiology reports(IF=3.3). 2017. PMID:28251513. DOI: 10.1007/s11886-017-0832-3.
  • [10] Amelia D Dahlén;Giovanna Dashi;Ivan Maslov;Misty M Attwood;Jörgen Jonsson;Vladimir Trukhan;Helgi B Schiöth. Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales.. Frontiers in pharmacology(IF=4.8). 2021. PMID:35126141. DOI: 10.3389/fphar.2021.807548.
  • [11] Peggy Soule Odegard;Stephen M Setter;Jason L Iltz. Update in the pharmacologic treatment of diabetes mellitus: focus on pramlintide and exenatide.. The Diabetes educator(IF=3.9). 2006. PMID:16971704. DOI: 10.1177/0145721706294003.
  • [12] Prabhsimran Kaur;Bidwan Sekhar Behera;Sandeep Singh;Anjana Munshi. "The pharmacological profile of SGLT2 inhibitors: Focus on mechanistic aspects and pharmacogenomics".. European journal of pharmacology(IF=4.7). 2021. PMID:33984301. DOI: 10.1016/j.ejphar.2021.174169.
  • [13] D Kaiser;E Oetjen. Something old, something new and something very old: drugs for treating type 2 diabetes.. British journal of pharmacology(IF=7.7). 2014. PMID:24641580. DOI: 10.1111/bph.12624.
  • [14] Ran Cheng;Nadine Taleb;Meggie Stainforth-Dubois;Rémi Rabasa-Lhoret. The promising future of insulin therapy in diabetes mellitus.. American journal of physiology. Endocrinology and metabolism(IF=3.1). 2021. PMID:33719586. DOI: 10.1152/ajpendo.00608.2020.
  • [15] Jerry D Meece;Teresa L Pearson;Linda M Siminerio. Complementary Approaches to Improving Glucose Control-Insulin and Incretins: Patient Case Studies in Action.. The Diabetes educator(IF=3.9). 2014. PMID:24841710. DOI: 10.1177/0145721714527802.
  • [16] Chirag Jain; Ansarullah;Sara Bilekova;Heiko Lickert. Targeting pancreatic β cells for diabetes treatment.. Nature metabolism(IF=20.8). 2022. PMID:36131204. DOI: 10.1038/s42255-022-00618-5.
  • [17] Muhammad Sarfraz Nawaz;Kifayat Ullah Shah;Tahir Mehmood Khan;Asim Ur Rehman;Haroon Ur Rashid;Sajid Mahmood;Shahzeb Khan;Muhammad Junaid Farrukh. Evaluation of current trends and recent development in insulin therapy for management of diabetes mellitus.. Diabetes & metabolic syndrome(IF=3.4). 2017. PMID:28709853. DOI: 10.1016/j.dsx.2017.07.003.
  • [18] R A Harrigan;M S Nathan;P Beattie. Oral agents for the treatment of type 2 diabetes mellitus: pharmacology, toxicity, and treatment.. Annals of emergency medicine(IF=5.0). 2001. PMID:11423816. DOI: 10.1067/mem.2001.114314.
  • [19] M C Riddle. Oral pharmacologic management of type 2 diabetes.. American family physician(IF=3.5). 1999. PMID:10605995. DOI: .
  • [20] Raj Padwal;Sumit R Majumdar;Jeff A Johnson;Janice Varney;Finlay A McAlister. A systematic review of drug therapy to delay or prevent type 2 diabetes.. Diabetes care(IF=16.6). 2005. PMID:15735219. DOI: 10.2337/diacare.28.3.736.
  • [21] Paolo Cavallo Perin;Paolo Fornengo. New oral antidiabetic agents.. Internal and emergency medicine(IF=3.8). 2011. PMID:22009626. DOI: 10.1007/s11739-011-0677-5.
  • [22] A C Asmal;A Marble. Oral hypoglycaemic agents. An update.. Drugs(IF=14.4). 1984. PMID:6378583. DOI: 10.2165/00003495-198428010-00004.
  • [23] Gwang Sil Kim;Joong Hyun Park;Jong Chul Won. The Role of Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Reducing Cardiovascular Events in Patients with Type 2 Diabetes.. Endocrinology and metabolism (Seoul, Korea)(IF=4.2). 2019. PMID:31099200. DOI: 10.3803/EnM.2019.34.2.106.
  • [24] Richard A Ferraro;Caitlin M Nass;Ramzi Dudum;Roger S Blumenthal;Sudipa Sarkar. What Clinicians Need to Know About the Cardiovascular Effects of the Most Recent Classes of Drugs Used for Type 2 Diabetes.. The American journal of medicine(IF=5.3). 2019. PMID:30904510. DOI: 10.1016/j.amjmed.2019.02.050.
  • [25] Brian Tomlinson;Miao Hu;Yuzhen Zhang;Paul Chan;Zhong-Min Liu. An overview of new GLP-1 receptor agonists for type 2 diabetes.. Expert opinion on investigational drugs(IF=4.1). 2016. PMID:26587691. DOI: 10.1517/13543784.2016.1123249.
  • [26] Roni Weinberg Sibony;Omri Segev;Saar Dor;Itamar Raz. Drug Therapies for Diabetes.. International journal of molecular sciences(IF=4.9). 2023. PMID:38138975. DOI: 10.3390/ijms242417147.
  • [27] Keong Chong;Jack Keng-Jui Chang;Lee-Ming Chuang. Recent advances in the treatment of type 2 diabetes mellitus using new drug therapies.. The Kaohsiung journal of medical sciences(IF=3.1). 2024. PMID:38183334. DOI: 10.1002/kjm2.12800.
  • [28] Karl Sebastian Johansson;David Peick Sonne;Filip Krag Knop;Mikkel Bring Christensen. What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipeline.. Expert opinion on drug discovery(IF=4.9). 2020. PMID:32646248. DOI: 10.1080/17460441.2020.1791078.
  • [29] Michael A Nauck;Jakob Wefers;Juris J Meier. Treatment of type 2 diabetes: challenges, hopes, and anticipated successes.. The lancet. Diabetes & endocrinology(IF=41.8). 2021. PMID:34181914. DOI: 10.1016/S2213-8587(21)00113-3.
  • [30] Melania Gaggini;Laura Sabatino;Adrian Florentin Suman;Kyriazoula Chatzianagnostou;Cristina Vassalle. Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology.. Cells(IF=5.2). 2025. PMID:40072115. DOI: 10.3390/cells14050387.
  • [31] Dimitra Vasdeki;Theocharis Koufakis;Georgios Tsamos;Luca Busetto;Pantelis Zebekakis;Kalliopi Kotsa. Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches.. Nutrients(IF=5.0). 2022. PMID:36432488. DOI: 10.3390/nu14224801.
  • [32] Maeve Moran. The evolution of the nutritional management of diabetes.. The Proceedings of the Nutrition Society(IF=4.5). 2004. PMID:15831134. DOI: 10.1079/pns2004392.
  • [33] Gita Chawla;Tathagata Pradhan;Ojasvi Gupta. An Insight into the Combat Strategies for the Treatment of Type 2 Diabetes Mellitus.. Mini reviews in medicinal chemistry(IF=3.3). 2024. PMID:37198989. DOI: 10.2174/1389557523666230517113936.
  • [34] Bantayehu Addis Tegegne;Adane Adugna;Aderaw Yenet;Wubetu Yihunie Belay;Yared Yibeltal;Abebe Dagne;Zigale Hibstu Teffera;Gashaw Azanaw Amare;Desalegn Abebaw;Haymanot Tewabe;Rahel Belete Abebe;Tirsit Ketsela Zeleke. A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents.. Frontiers in endocrinology(IF=4.6). 2024. PMID:39493778. DOI: 10.3389/fendo.2024.1440456.
  • [35] Emilia Pauline Liao. Management of type 2 diabetes: new and future developments in treatment.. The American journal of medicine(IF=5.3). 2012. PMID:22998892. DOI: .
  • [36] G Nicholson;G M Hall. Diabetes mellitus: new drugs for a new epidemic.. British journal of anaesthesia(IF=9.2). 2011. PMID:21610015. DOI: 10.1093/bja/aer120.
  • [37] Marion L Vetter;Lucy F Faulconbridge;Victoria L Webb;Thomas A Wadden. Behavioral and pharmacologic therapies for obesity.. Nature reviews. Endocrinology(IF=40.0). 2010. PMID:20680034. DOI: 10.1038/nrendo.2010.121.
  • [38] Michelle I Cardel;Kathryn M Ross;Meghan Butryn;W Troy Donahoo;Abraham Eastman;Julia R Dillard;Anna Grummon;Patrick Hopkins;Leah D Whigham;David Janicke. Acceptance-based therapy: the potential to augment behavioral interventions in the treatment of type 2 diabetes.. Nutrition & diabetes(IF=5.2). 2020. PMID:32066659. DOI: 10.1038/s41387-020-0106-9.
  • [39] R S Surwit;A W Scovern;M N Feinglos. The role of behavior in diabetes care.. Diabetes care(IF=16.6). 1982. PMID:6756844. DOI: 10.2337/diacare.5.3.337.
  • [40] Juan José Marín-Peñalver;Iciar Martín-Timón;Cristina Sevillano-Collantes;Francisco Javier Del Cañizo-Gómez. Update on the treatment of type 2 diabetes mellitus.. World journal of diabetes(IF=4.6). 2016. PMID:27660695. DOI: 10.4239/wjd.v7.i17.354.
  • [41] Gary Scheiner;Robert J Sobel;Daphne E Smith;Anthony J Pick;Davida Kruger;Jacqueline King;Karen Green. Insulin pump therapy: guidelines for successful outcomes.. The Diabetes educator(IF=3.9). 2009. PMID:19318690. DOI: 10.1177/0145721709333493.
  • [42] Maleeha Zahid;Samaneh Dowlatshahi;Abhishek H Kansara;Archana R Sadhu. The Evolution of Diabetes Technology - Options Toward Personalized Care.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists(IF=4.6). 2023. PMID:37100350. DOI: 10.1016/j.eprac.2023.04.007.
  • [43] Margaretha M Visser;Roman Vangoitsenhoven;Pieter Gillard;Chantal Mathieu. Review Article - Diabetes Technology in the Hospital: An Update.. Current diabetes reports(IF=6.4). 2024. PMID:38842632. DOI: 10.1007/s11892-024-01545-3.
  • [44] Erika L Lundgrin;Clare A Kelly;Natalie Bellini;Claudia Lewis;Ebne Rafi;Betul Hatipoglu. Diabetes Technology Trends: A Review of the Latest Innovations.. The Journal of clinical endocrinology and metabolism(IF=5.1). 2025. PMID:39998918. DOI: 10.1210/clinem/dgaf034.
  • [45] Jordan S Sherwood;Steven J Russell;Melissa S Putman. New and Emerging Technologies in Type 1 Diabetes.. Endocrinology and metabolism clinics of North America(IF=4.2). 2020. PMID:33153673. DOI: 10.1016/j.ecl.2020.07.006.
  • [46] Jelena Kravarusic;Grazia Aleppo. Diabetes Technology Use in Adults with Type 1 and Type 2 Diabetes.. Endocrinology and metabolism clinics of North America(IF=4.2). 2020. PMID:31980120. DOI: 10.1016/j.ecl.2019.10.006.
  • [47] Klemen Dovc;Tadej Battelino. Evolution of Diabetes Technology.. Endocrinology and metabolism clinics of North America(IF=4.2). 2020. PMID:31980111. DOI: 10.1016/j.ecl.2019.10.009.
  • [48] David M Williams;Hannah Jones;Jeffrey W Stephens. Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations.. Diabetes, metabolic syndrome and obesity : targets and therapy(IF=3.0). 2022. PMID:35153495. DOI: 10.2147/DMSO.S331654.
  • [49] Ammira Al-Shabeeb Akil;Esraa Yassin;Aljazi Al-Maraghi;Elbay Aliyev;Khulod Al-Malki;Khalid A Fakhro. Diagnosis and treatment of type 1 diabetes at the dawn of the personalized medicine era.. Journal of translational medicine(IF=7.5). 2021. PMID:33794915. DOI: 10.1186/s12967-021-02778-6.
  • [50] E R Pearson. Personalized medicine in diabetes: the role of 'omics' and biomarkers.. Diabetic medicine : a journal of the British Diabetic Association(IF=3.4). 2016. PMID:26802434. DOI: 10.1111/dme.13075.
  • [51] David C Klonoff. The personalized medicine for diabetes meeting summary report.. Journal of diabetes science and technology(IF=3.7). 2009. PMID:20144312. DOI: 10.1177/193229680900300410.
  • [52] Noemi Malandrino;Robert J Smith. Personalized medicine in diabetes.. Clinical chemistry(IF=6.3). 2011. PMID:21127150. DOI: 10.1373/clinchem.2010.156901.
  • [53] Peter S Linsley;Carla J Greenbaum;Gerald T Nepom. Uncovering Pathways to Personalized Therapies in Type 1 Diabetes.. Diabetes(IF=7.5). 2021. PMID:33741606. DOI: 10.2337/db20-1185.
  • [54] Alice L J Carr;Carmella Evans-Molina;Richard A Oram. Precision medicine in type 1 diabetes.. Diabetologia(IF=10.2). 2022. PMID:35994083. DOI: 10.1007/s00125-022-05778-3.
  • [55] André J Scheen. Precision medicine: The future in diabetes care?. Diabetes research and clinical practice(IF=7.4). 2016. PMID:27329017. DOI: .
  • [56] Laura M Jacobsen;Jennifer L Sherr;Elizabeth Considine;Angela Chen;Sarah M Peeling;Margo Hulsmans;Sara Charleer;Marzhan Urazbayeva;Mustafa Tosur;Selma Alamarie;Maria J Redondo;Korey K Hood;Peter A Gottlieb;Pieter Gillard;Jessie J Wong;Irl B Hirsch;Richard E Pratley;Lori M Laffel;Chantal Mathieu; . Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review.. Communications medicine(IF=6.3). 2023. PMID:37794113. DOI: 10.1038/s43856-023-00358-x.
  • [57] Itamar Raz;Matthew C Riddle;Julio Rosenstock;John B Buse;Silvio E Inzucchi;Philip D Home;Stefano Del Prato;Ele Ferrannini;Juliana C N Chan;Lawrence A Leiter;Derek Leroith;Ralph Defronzo;William T Cefalu. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum.. Diabetes care(IF=16.6). 2013. PMID:23704680. DOI: 10.2337/dc13-0512.
  • [58] René Rodríguez-Gutiérrez;Juan Manuel Millan-Alanis;Francisco J Barrera;Rozalina G McCoy. Value of Patient-Centered Glycemic Control in Patients with Type 2 Diabetes.. Current diabetes reports(IF=6.4). 2021. PMID:34902079. DOI: 10.1007/s11892-021-01433-0.
  • [59] Devin Steenkamp;Elizabeth L Eby;Nany Gulati;Birong Liao. Adherence and Persistence to Insulin Therapy in People with Diabetes: Impact of Connected Insulin Pen Delivery Ecosystem.. Journal of diabetes science and technology(IF=3.7). 2022. PMID:33666097. DOI: 10.1177/1932296821997923.
  • [60] Dian-Bao Zuo;Chun-Hua Wang;Ming Sang;Xiao-Dong Sun;Guo-Ping Chen;Kang-Kang Ji. Stem cell therapy for diabetes: Advances, prospects, and challenges.. World journal of diabetes(IF=4.6). 2025. PMID:40697599. DOI: 10.4239/wjd.v16.i7.107344.
  • [61] Sanchit Dhankhar;Samrat Chauhan;Dinesh Kumar Mehta; Nitika;Kamal Saini;Monika Saini;Rina Das;Sumeet Gupta;Vinod Gautam. Novel targets for potential therapeutic use in Diabetes mellitus.. Diabetology & metabolic syndrome(IF=3.9). 2023. PMID:36782201. DOI: 10.1186/s13098-023-00983-5.
  • [62] Shazia Hussain;Tahseen A Chowdhury. The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus.. Drugs(IF=14.4). 2019. PMID:30742277. DOI: 10.1007/s40265-019-1061-4.
  • [63] Jade I Basem;Fatoumata N Bah;Neel D Mehta. A Brief Review on the Novel Therapies for Painful Diabetic Neuropathy.. Current pain and headache reports(IF=3.5). 2023. PMID:37392335. DOI: 10.1007/s11916-023-01126-1.
  • [64] Julia Teck. Diabetes-Associated Comorbidities.. Primary care(IF=4.3). 2022. PMID:35595482. DOI: 10.1016/j.pop.2021.11.004.
  • [65] Jin Yu;Seung-Hwan Lee;Mee Kyoung Kim. Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus.. Endocrinology and metabolism (Seoul, Korea)(IF=4.2). 2022. PMID:35255599. DOI: 10.3803/EnM.2022.105.
  • [66] Chuyun Zhao;Wenjie Lai;Yu Li;Kinfong Hong;Youhua Xu. Potential and Mechanism of Nobiletin in Diabetes Mellitus and Associated Complications.. Pharmaceuticals (Basel, Switzerland)(IF=4.8). 2025. PMID:41155643. DOI: 10.3390/ph18101528.
  • [67] Hao Yang;Yujie Wang;Shan Xu;Jie Ren;Lidan Tang;Jinhong Gong;Ying Lin;Hufeng Fang;Dan Su. Hesperetin, a Promising Treatment Option for Diabetes and Related Complications: A Literature Review.. Journal of agricultural and food chemistry(IF=6.2). 2022. PMID:35801973. DOI: 10.1021/acs.jafc.2c03257.

MaltSci Intelligent Research Services ​

Search for more papers on MaltSci.com ​

Diabetes · Pharmacological Treatments · Personalized Medicine · Lifestyle Modifications · Emerging Technologies

© 2025 MaltSci